Viridian Therapeutics Inc. Common Stock (VRDN)
Stock · NASDAQ · Health Care
$19.05as of 10/16/2026
Price chart
Active signals
VRDN Signal Track Record
How signals performed across all stocks →What VRDN's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | +1.2% | 55% | September 23, 2026 |
| Bollinger Band Breakdown | 22 | -2.7% | 36% | September 29, 2026 |
| Bollinger Band Breakout | 23 | +8.1% | 78% | August 4, 2026 |
| 200-Day Moving Average TouchActive now | 13 | -6.2% | 15% | August 18, 2026 |
| Any 20-session window (baseline) | -0.2% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VRDN
Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered, and Elegrobart, a low-volume, infrequently dosed subcutaneous IGF-1R. The company also develops an anti-thyroid-st…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 252
Fundamentals
- 1-day range
- $18.94$19.78
- Market cap
- $2.32B
- P/E (trailing)
- —
- P/E (forward)
- -6.91
- EPS (trailing)
- $-3.90
- Dividend yield
- —
- Beta
- 1.11
- Avg. volume
- 1.77M
- Dividend pay date
- November 13, 2020
How Viridian Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
16 analyst ratings
Viridian Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VRDNViridian Therapeutics Inc. Common Stock$19.03▼ 2.71%Market cap $2.32BP/E —$13.18$34.29
- VERAVera Therapeutics Inc. Class A Common Stock$27.88▼ 2.42%Market cap $2.30BP/E —$23.05$56.05
- ZLABZai Lab Limited American Depositary Shares$23.19▼ 1.36%Market cap $2.35BP/E —$12.31$26.6
- HRMYHarmony Biosciences Holdings Inc. Common Stock$37.95▼ 0.84%Market cap $2.26BP/E 12.36$25.52$43.49
- PHVSPharvaris N.V. Ordinary Shares$27.74▼ 6.41%Market cap $2.40BP/E —$20.65$43.25
- SIONSionna Therapeutics Inc. Common Stock$3.89▼ 4.66%Market cap $2.24BP/E —$3.93$54.97
- PVLAPalvella Therapeutics Inc. Common Stock$120.3▼ 5.53%Market cap $2.23BP/E —$68.96$161.38
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VRDN Viridian Therapeutics Inc. Common Stock | $2.32B | — | $19.03 | ▼ 2.71% | $13.18$34.29 |
| VERA Vera Therapeutics Inc. Class A Common Stock | $2.30B | — | $27.88 | ▼ 2.42% | $23.05$56.05 |
| ZLAB Zai Lab Limited American Depositary Shares | $2.35B | — | $23.19 | ▼ 1.36% | $12.31$26.6 |
| HRMY Harmony Biosciences Holdings Inc. Common Stock | $2.26B | 12.36 | $37.95 | ▼ 0.84% | $25.52$43.49 |
| PHVS Pharvaris N.V. Ordinary Shares | $2.40B | — | $27.74 | ▼ 6.41% | $20.65$43.25 |
| SION Sionna Therapeutics Inc. Common Stock | $2.24B | — | $3.89 | ▼ 4.66% | $3.93$54.97 |
| PVLA Palvella Therapeutics Inc. Common Stock | $2.23B | — | $120.3 | ▼ 5.53% | $68.96$161.38 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Roche Secures FDA Approval for First At-Home Thyroid Eye Disease Therapybenzinga · 10/16/2026
- Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC SaysYahoo · 9/22/2026
- RBC Capital Maintains Outperform on Viridian Therapeutics, Raises Price Target to $38Benzinga · 9/22/2026
- Viridian Therapeutics: Two Products, One Commercial BuildoutSeekingAlpha · 9/17/2026
Insider Activity
Insider Actions →- Tousignant Jennifer · August 19, 2026 · Option Exercise10.0K @ $14.41
- Tousignant Jennifer · August 19, 2026 · Sale10.0K @ $24.5
- Tousignant Jennifer · August 19, 2026 · Sale4.2K @ $24.5
- Tripuraneni Radhika · August 14, 2026 · Option Exercise40.0K @ $13.21
- CAIN CHRISTOPHER W. · July 1, 2026 · Grant32.3K
- Moses Jennifer K. · July 1, 2026 · Grant32.3K
- Gheuens Sarah · July 1, 2026 · Grant32.3K
- Kiselak Tomas · July 1, 2026 · Grant32.3K
- Ajer Jeffrey Robert · July 1, 2026 · Grant32.3K
- Arlene Morris · July 1, 2026 · Grant32.3K
- Fairmount Healthcare Fund II L.P. · May 11, 2026 · Buy1.18M @ $17
Institutional Ownership
March 31, 2026
- Total shares held
- 109.40M
- Total value held
- $2.08B
- Institutional holders
- 218
- Unknown15.38M
- Unknown7.83M
- Unknown6.73M
- Unknown4.67M
- Unknown4.17M
- Unknown3.91M
- Unknown3.88M
- Unknown3.21M
- Unknown3.15M
- Unknown3.08M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
VRDN Draws Institutional Interest; Set for Wells Fargo Healthcare Conference
Viridian Therapeutics has attracted attention as a healthcare specialist identified it among four biotech stocks of interest, according to Benzinga. The company is scheduled to present at the Wells Fargo Healthcare Conference, a routine industry event for biotech firms seeking investor engagement. The stock is currently trading within its 52-week range of $13.18 to $34.29, while analysts maintain an average price target of $36.62 based on 16 estimates.
VRDN Draws Institutional Interest; Set for Wells Fargo Healthcare Conference. Viridian Therapeutics has attracted attention as a healthcare specialist identified it among four biotech stocks of interest, according to Benzinga. The company is scheduled to present at the Wells Fargo Healthcare Conference, a routine industry event for biotech firms seeking investor engagement. The stock is currently trading within its 52-week range of $13.18 to $34.29, while analysts maintain an average price target of $36.62 based on 16 estimates.